Group 1 - The company plans to conduct foreign exchange derivative trading in 2026 to mitigate risks associated with foreign exchange rate and interest rate fluctuations, with a total trading limit not exceeding 75 million RMB or equivalent foreign currency [4][10]. - The trading will primarily utilize the company's own funds and will not involve raised funds [5][6]. - The company will employ simple and transparent foreign exchange derivative instruments, such as forward contracts and options, with a maximum duration of 12 months [6][8]. Group 2 - The company has approved the use of up to 150 million RMB of temporarily idle raised funds for cash management, focusing on safe and liquid investment products with a maturity of no more than 12 months [21][24]. - The investment aims to enhance the efficiency of raised fund usage while ensuring that it does not affect the ongoing projects funded by these raised funds [23][38]. - The company will strictly control risks associated with these investments and will not use the funds for speculative purposes [35][50]. Group 3 - The company plans to provide a maximum guarantee of 320 million RMB for its subsidiaries' bank loans in 2026, which will enhance financing efficiency [53][60]. - The guarantee is based on the current business situation and is expected to be within a controllable risk range [54][61]. - The company has no overdue guarantees or litigation-related guarantees, ensuring a stable financial position [62]. Group 4 - The company anticipates daily related transactions with specific affiliated companies, with a total expected amount not exceeding 18.5 million RMB for 2026 [67][70]. - These transactions are necessary for the company's normal business operations and are conducted at market prices to ensure fairness [75][76]. - The company has established contracts with related parties to ensure compliance and protect shareholder interests [73][74]. Group 5 - The company intends to apply for a financing limit of up to 300 million RMB from banks and financial institutions in 2026, using its own assets as collateral [78][79]. - This financing is aimed at meeting the operational funding needs of the company and its subsidiaries without adversely affecting business operations [80].

格隆汇1月4日丨科兴制药(688136.SH)公布，截至2025年12月31日，公司通过上海证券交易所交易系统 以集中竞价交易方式已累计回购公司股份131.93万股，占公司目前总股本比例为0.66%，回购成交的最 高价为43.50元/股，最低价为23.14元/股，支付的资金总额为人民币4,924.18万元(不含交易佣金等费 用)。 ...

Policy Developments - The State Council approved the revised draft of the Drug Administration Law Implementation Regulations, emphasizing the importance of timely revisions to drug management laws for ensuring public safety and promoting the healthy development of the pharmaceutical industry [1] Industry Initiatives - Hainan Province aims to develop over six distinctive traditional Chinese medicine health tourism routes by the end of 2028, with a target of cultivating over 1 million mu of medicinal herb planting and breeding areas, and achieving a 15% growth in the overall output value of traditional Chinese medicine [2] Drug and Medical Device Approvals - Xingqi Eye Medicine announced the approval of its atropine sulfate eye drops for children aged 6 to 12, with new product specifications added [1] Capital Market Activities - Sinovac Biotech has repurchased approximately 1.32 million shares, accounting for 0.66% of its total share capital, with a total expenditure of approximately RMB 49.24 million [3] - Dongcheng Pharmaceutical plans to repurchase shares worth between RMB 100 million and RMB 200 million for employee stock ownership plans, with a maximum repurchase price of RMB 18.00 per share [4] - Haizheng Pharmaceutical's major shareholder intends to transfer 6.06% of the company's shares through a public solicitation, pending approval from relevant authorities [5] Strategic Collaborations - Sinopharm Holdings and Betta Pharmaceuticals have signed a strategic cooperation agreement to enhance collaboration and create a new efficient pharmaceutical supply chain ecosystem [6] Personnel Changes - The independent director of Nanxin Pharmaceutical, Shen Yunqiao, has resigned for personal reasons, and will continue to fulfill his duties until a new independent director is elected [7]

证券日报网讯 1月4日，科兴制药发布公告称，截至2025年12月31日，公司通过上海证券交易所交易系 统以集中竞价交易方式已累计回购公司股份1，319，333股，占公司目前总股本比例为0.66%，回购成 交的最高价为43.50元/股，最低价为23.14元/股，支付的资金总额为人民币4，924.18万元（不含交易佣 金等费用）。 （编辑 王江浩） ...

证券代码：688136 证券简称：科兴制药 公告编号：2026-008 重要内容提示： 科兴生物制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司 2025 年 5 月 8 日召开第二届董事会第二十四次会议审议通过了《关于调 整回购股份价格上限的议案》，将回购股份价格上限调整为人民币 46.83 元/股（含）。 具体内容详见公司于2025年5月9日披露在上海证券交易所网站（www.sse.com.cn） 的《关于调整回购股份价格上限的公告》（公告编号：2025-024）。 鉴于公司 2024 年年度权益分派已实施完毕，公司以集中竞价交易方式回购股 份价格上限由不超过人民币46.83元/股（含）调整为不超过人民币46.75元/股（含）。 具 体 内 容 详 见 公 司 于 2025 年 6 月 21 日 披 露 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）的《关于 2024 年年度权益分派实施后调整回购价格上限的公 告》（公告编号：20 ...

Core Insights - The successful IPO of Insilico Medicine (stock code: 3696.HK) on the Hong Kong Stock Exchange marks the largest fundraising in the Hong Kong biopharmaceutical sector this year, highlighting the capital market's recognition of AI-driven drug development [1] - Insilico Medicine's partnership with MediXis (stock code: 688202.SH) has gained new attention and industry imagination, emphasizing the critical role of MediXis as a preclinical research service provider in the AI drug development wave [1] Group 1: AI and CRO Integration - The collaboration between Insilico Medicine and MediXis has transformed the drug development paradigm, with MediXis demonstrating efficient and stable delivery capabilities in various tumor projects, enabling rapid clinical progression of AI-discovered molecules [2] - This partnership represents a deep integration of service procurement and technical processes, with Insilico leveraging its Pharma.AI platform for breakthroughs in target discovery and molecular generation, while MediXis provides comprehensive preclinical services [2] Group 2: Expansion of Services and Capabilities - By mid-2025, MediXis has empowered approximately 588 IND approvals, with projects in collaboration with Insilico serving as successful examples of the "AI-driven development + professional CRO execution" model, enhancing both companies' efficiency and experience in AI drug development [3] - MediXis has expanded its AI drug discovery service platform, exploring new therapies such as PROTAC, ADC, nucleic acid drugs, and cell and gene therapies, showcasing its comprehensive strategic layout and capability evolution [4] Group 3: Industry Leadership and Global Strategy - MediXis has solidified its industry-leading position through systematic capability building, achieving breakthroughs in service granularity, technological foresight, compliance systems, and global expansion [4] - The company has successfully obtained various GLP qualifications and enhanced its competitiveness in international preclinical research, with a growing proportion of revenue from overseas clients and increased new order amounts [5] Group 4: Future Outlook - The successful listing of Insilico Medicine signifies a milestone in the capitalization and industrialization of AI drug development, positioning MediXis as an indispensable verification and efficiency engine within the AI drug development ecosystem [6] - As the demand for high-efficiency and high-reliability preclinical research services continues to grow, MediXis is well-positioned to strengthen its leading role as a preclinical research enabler by deepening collaborations with cutting-edge technology companies like Insilico [6]

Core Viewpoint - Sinovac has been awarded the exclusive contract to supply over 8 million doses of flu vaccine to the Chilean government for the 2026 fiscal year, reinforcing its position in the market and demonstrating its product quality and international compliance capabilities [1] Group 1: Contract and Supply Details - The first batch of vaccines is scheduled to arrive in Chile by the end of January 2026 to meet the upcoming flu season's demand [1] - Sinovac has been the sole supplier of flu vaccines in Chile for two consecutive years, indicating a strong recognition from the Chilean public health system [1] Group 2: Previous Performance - In 2025, Sinovac supplied over 8.3 million doses of flu vaccine in Chile, achieving approximately 80% vaccination coverage of the target population [1]

格隆汇12月31日丨科兴制药(688136.SH)公布，在保证不影响公司募集资金投资计划正常进行的前提 下，公司及全资子公司拟使用最高不超过人民币1.5亿元（包含本数）的暂时闲置募集资金进行现金管 理，额度使用期限为自董事会审议通过之日起12个月内有效。在前述额度及期限范围内，资金可以循环 滚动使用。 ...

证券代码：688136 证券简称：科兴制药 公告编号：2026-001 科兴生物制药股份有限公司 关于 2026 年度开展外汇衍生品交易业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易主要情况 | | □获取投资收益 | | | --- | --- | --- | | 交易目的 | √套期保值（合约类别：□商品；√外汇；□其他：________） □其他：________ | | | 交易品种 | 包括且不限于外汇远期、外汇期权、外汇掉期等外汇衍生工具 | | | 交易金额 | 预计动用的交易保证金和权利金上限（单位：万元） | 450 | | | 预计任一交易日持有的最高合约价值（单位：万元） | 7,500 | | 资金来源 | √自有资金 □借贷资金 □其他：___ | | | 交易期限 | 2025年12月30日至2026年12月29日 | | 已履行及拟履行的审议程序 随着海外商业化的不断推进，公司国际业务的外汇收付金额较大，为规避外 汇汇率/利率波动带来的风险，公司拟开展外汇衍生品交 ...

证券代码：688136 证券简称：科兴制药 公告编号：2026-003 科兴生物制药股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 不超过 万元 | 40,000 | | --- | --- | --- | | 投资种类 | 安全性高、流动性好、风险较低的理财产品 | | | 资金来源 | 自有资金 | | 已履行及拟履行的审议程序 特别风险提示 尽管公司拟投资安全性高、流动性好、风险较低的产品。但金融市场受宏观 经济的影响较大，公司将根据经济形势以及金融市场的变化适时适量地介入，但 不排除该项投资受到市场波动的影响，存在一定的系统性风险。 一、投资情况概述 （一）投资目的 为进一步提高公司闲置自有资金使用效率，在不影响公司主营业务的正常发 展并确保公司经营资金需求的前提下，合理利用自有资金，增加公司投资收益， 为公司及股东获取更多回报。 （二）投资金额及期限 公司拟使用额度不超过人民币 4 亿元（含本数）的闲置自有资金购买理 ...